Filter results
27/11/2020
The results of the phase III pivotal clinical trial show that the once-monthly injectable antipsychotic Doria® furnishes a significant improvement in the symptomatology and severity of the illness in patients with acute exacerbation of schizophrenia.
24/11/2020
ROVI updates its strategy in a meeting with shareholders, investors and analysts.
05/11/2020
Operating income, growth figures, profitability and how our products have behaved.
05/11/2020
Download our press release published on 5 November to find out the financial results for the first nine months of 2020.
20/10/2020
ROVI increases operating income by 26% and net profit by 119% in 2019
27/07/2020
Operating income, growth figures, profitability and how our products have behaved.
27/07/2020
Download our press release published on 27 July to find out the financial results for the first half of 2020.